drugset / Trial / NCT03476109
Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.
Phase 4
Unknown
100 enrolled
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
AZ Delta · collabBrugmann University Hospital · collabCHU de Charleroi · collabCentre Hospitalier Universitaire Saint Pierre · collabCentre Hospitalier Universitaire UCLouvain Namur · collabErasme University Hospital · collabGrand Hôpital de Charleroi · collabKU Leuven · collabUniversitair Ziekenhuis Brussel · collabUniversity Hospital, Ghent · collabUniversity of Liege · collab
RandomizedFactorialSingle-blindTreatment
Summary
Pragmatic trial to define the magnitude and the predictive factors of the response to omalizumab and mepolizumab in adult patients with severe refractory asthma and eligible to both therapies.
Timeline
- Start
- 2019-05-10
- Primary completion
- 2023-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mepolizumab | Monoclonal antibody | — | — |
| Comparator | Omalizumab | Monoclonal antibody | — | — |